Cassava Sciences Q3 2023 Earnings Report

Cassava Sciences EPS Results

• Actual EPS: -$0.44
• Consensus EPS: -$0.64
• Beat/Miss: Beat by +$0.21
• One Year Ago EPS: N/A

Cassava Sciences Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Cassava Sciences Announcement Details

• Quarter: Q3 2023
• Date: 11/7/2023
• Time: N/A
• Conference Call Date: Tuesday, November 7, 2023
• Conference Call Time: 7:00AM ET

Cassava Sciences (NASDAQ:SAVA) (NASDAQ: SAVA) is a clinical-stage biotechnology company focused on developing novel therapies for Alzheimer’s disease and other neurodegenerative disorders. Founded in 1998 and headquartered in Austin, Texas, the company originally operated under the name Pain Therapeutics before rebranding to Cassava Sciences in 2015. Its research platform centers on small-molecule compounds designed to restore cognitive function by targeting underlying disease mechanisms rather than simply addressing symptoms.

The company’s lead investigational drug candidate is simufilam, a proprietary small molecule that aims to normalize altered brain proteins implicated in Alzheimer’s pathology. Simufilam is currently being evaluated in late-stage clinical trials, including Phase 3 studies, while Cassava Sciences also conducts biomarker and imaging analyses to support its development program. In addition to its core Alzheimer’s pipeline, the company explores diagnostic approaches to better characterize patient populations and track therapeutic effects over time.

Cassava Sciences operates primarily in the United States but has extended its clinical trial footprint to multiple international sites, collaborating with academic centers and research institutions to advance its programs. The company maintains partnerships with leading universities and contract research organizations to support patient recruitment, data collection and regulatory filings. Through these alliances, Cassava Sciences seeks to accelerate the translation of laboratory discoveries into potential treatment breakthroughs.

The executive leadership team is led by President and Chief Executive Officer Remi Barbier, who has guided the company’s strategic direction since 2004. Under his stewardship, Cassava Sciences has built a specialized research and development organization staffed by neuroscientists, clinicians and regulatory experts. The board of directors includes veteran life-science executives and scientific advisors whose collective experience spans drug discovery, clinical development and commercial strategy in the biopharmaceutical sector.